Table 1.
Major transplantation characteristics of all disease categories.
| No | Age | CD34+ stem cell dose (× 106/kg) | Time to neutrophil engraftment (days) | Time to platelet engraftment (days) | Graft rejection | AGVHD (grade II–IV) | CGVHDa | TRM | |
|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD (Range) | Mean ± SD (Range) | Mean ± SD (Range) | Mean ± SD (Range) | No (%) | No (%) | No (%) | No (%) | ||
| SAA | 273 | 19.7 ± 0.54 (1.5–51) | 8.9 ± 0.32 (3.1–24.4) | 13.9 ± 0.36 (10–26) | 14.1 ± 0.61 (8–83) | 3/273 (1%) | 42/273 (15%) | 70/248 (28%) | 60/273 (22%) |
| BTM | 152 | 5.7 ± 0.35 (1.1–23) | 12.6 ± 0.66 (2–49) | 21.4 ± 0.64 (8–69) | 32.8 ± 1.7 (7–134) | 17/152 (11.2%) | 23/152 (15%) | 16/133 (12%) | 28/152 (18%) |
| PB: 9% | |||||||||
| BM: 25% | |||||||||
| (p = 0.036)b | |||||||||
| FA | 31 | 11.7 ± 0.8 (6–26) | 11.6 ± 1.7 (2–56) | 11.1 ± 1.2 (9–26) | 12.3 ± 1.9 (9–45) | 3/31 (10%) | 5/31 (16%) | 1/24 (4%) | 10/31 (32%) |
| ID | 20 | 2.4 ± 0.55 (1–10) | 21.1 ± 3.0 (4.3–45) | 15.4 ± 1.1 (9–22) | 16.4 ± 2.3 (8–40) | 2/20 (10%) | 3/20 (15%) | 2/14 (14%) | 7/20 (35%) |
| IMD | 13 | 3 ± 0.66 (1–7) | 13.4 ± 1.7 (5.8–28.6) | 17.8 ± 2.2 (11–32) | 17.3 ± 1.6 (12–23) | 1/13 (8%) | 2/13 (15%) | 1/7 (14%) | 7/13 (54%) |
a
Patients were evaluated for cGVHD if they survived for at least 100 days after HSCT.
b
P value was calculated by independent samples t-tests.